Drugmaker XenoPort Inc and its partner GlaxoSmithKline Plc said the US health regulator approved their drug to treat shingles related nerve pain that may cause disability in some people. XenoPort will get a milestone payment of $10 million from Glaxo following first sales of the drug, Horizant, to...
FULL ARTICLE AT BDNews24